Matthew Stanton - Sep 10, 2021 Form 4 Insider Report for Generation Bio Co. (GBIO)

Role
CHIEF SCIENTIFIC OFFICER
Signature
/s/ Jennifer Elliott, Attorney-in-Fact
Stock symbol
GBIO
Transactions as of
Sep 10, 2021
Transactions value $
-$64,140
Form type
4
Date filed
9/14/2021, 04:02 PM
Previous filing
Aug 25, 2021
Next filing
Sep 16, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GBIO Common Stock Options Exercise $13.8K +3K +1.51% $4.59 201K Sep 10, 2021 Direct F1
transaction GBIO Common Stock Sale -$56.5K -2.2K -1.09% $25.69* 199K Sep 10, 2021 Direct F1, F2
transaction GBIO Common Stock Sale -$21.4K -800 -0.4% $26.74* 198K Sep 10, 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GBIO Stock Option (right to buy) Options Exercise $0 -3K -3.22% $0.00 90.1K Sep 10, 2021 Common Stock 3K $4.59 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 24, 2020.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.53 to $26.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) of this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.55 to $27.14, inclusive.
F4 The option to purchase 108,305 shares of common stock was granted on April 2, 2018. The shares underlying the option vest over four years, with 25% of the shares vested on April 2, 2019 and the remaining shares vesting in equal quarterly installments thereafter.